The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Targeting Disease Remission in Axial Spondyloarthritis: A Systematic Literature Review

被引：0
|
作者：
Machado, Ana Rita [1 ,2 ]
Manica, Santiago Rodrigues [3 ,4 ]
Silva, Joana Leite [5 ]
Pimentel-Santos, Fernando [3 ,4 ]
Costa, Jose Tavares [5 ]
Vieira-Sousa, Elsa [1 ,2 ]
机构：
[1] Univ Lisbon, Ctr Acad Med Lisboa, Fac Med, Unidade Invest Reumatol,Inst Med Mol, Lisbon, Portugal
[2] Ctr Hosp Lisboa Norte, Hosp Santa Maria, Serv Reumatol & Doencas Osseas Metab, Lisbon, Portugal
[3] Ctr Hosp Lisboa Ocidental, EPE, Hosp Egas Moniz, Rheumatol, Lisbon, Portugal
[4] NOVA Med Sch, CEDOC, Lisbon, Portugal
[5] Unidade Local Saude Alto Minho, Rheumatol, Ponte do Lima, Portugal
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2573
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Conventional and Biologic Disease-Modifying Antirheumatic Drugs Are Not Associated With Increase in or Progression of Cervical Neoplasia Among Patients With Spondyloarthritis
    Li, Philip Hei
    Chan, Shirley Chiu Wai
    Lau, Chak Sing
    Seto, Mimi Tin Yan
    Chung, Ho Yin
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2022, 28 (01) : E63 - E68
  • [42] Cost-Effectiveness of Biologic Response Modifiers Compared to Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Systematic Review
    van der Velde, Gabrielle
    Pham, Ba'
    Machado, Marcio
    Ieraci, Luciano
    Witteman, William
    Bombardier, Claire
    Krahn, Murray
    ARTHRITIS CARE & RESEARCH, 2011, 63 (01) : 65 - 78
  • [43] Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review
    Armstrong, April W.
    Brezinski, Elizabeth A.
    Follansbee, Matthew R.
    Armstrong, Ehrin J.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (04) : 500 - 512
  • [44] TIME TO INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE FRENCH COHORT ESPOIR
    Joanna, Kedra
    Granger, Benjamin
    Emilie, Stephanie
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Combe, Bernard
    Fautrel, Bruno
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1147 - 1148
  • [45] Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
    Razak, Salmi Abdul
    Bakry, Mohd Makmor
    Said, Mohd Shahrir Mohamed
    Tan, Chai-Eng
    Redzuan, Adyani Md
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [46] Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases
    Fazaa, Alia
    Makhlouf, Yasmine
    Ben Ouhiba, Amad
    Miladi, Saoussen
    Sellami, Mariem
    Ouenniche, Kmar
    Souabni, Leila
    Kassab, Salma
    Chekili, Selma
    Zakraoui, Leith
    Ben Abdelghani, Kawther
    Laatar, Ahmed
    THERAPIE, 2021, 76 (05): : 467 - 474
  • [47] Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR
    Kedra, Joanna
    Granger, Benjamin
    Emilie, Stephanie
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Combe, Bernard
    Fautrel, Bruno
    JOINT BONE SPINE, 2021, 88 (01)
  • [48] Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children
    Cron, Randy Q.
    CURRENT OPINION IN RHEUMATOLOGY, 2022, 34 (05) : 274 - 279
  • [49] Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Singh, Abha Goyal
    Hughes, Grant C.
    Pioro, Mathilde
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    JAMA NETWORK OPEN, 2024, 7 (11)
  • [50] The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
    Goralczyk, Alicja
    Kolossa, Katarzyna
    Waszczak-Jeka, Marzena
    Adamczak, Rafal
    Jeka, Slawomir
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (03): : 306 - 312
12345